Phoslo is a prescription phosphate binder medication specifically formulated for patients with end-stage renal disease (ESRD) undergoing dialysis. It works by binding dietary phosphate in the digestive tract, preventing its absorption into the bloodstream. Effective phosphate management is critical in reducing the risk of cardiovascular complications and mineral bone disorders associated with chronic kidney disease. This medication is a cornerstone therapy in nephrology, supporting long-term patient outcomes by maintaining serum phosphate within target ranges.

Features

• Contains calcium acetate as the active phosphate-binding ingredient
• Available in 667 mg tablets for precise dosing
• Designed to be taken with meals to maximize phosphate binding efficiency
• Vegan-friendly formulation (contains no animal-derived ingredients)
• Manufactured under strict pharmaceutical quality controls
• Packaged in light-resistant bottles to maintain stability

Benefits

• Effectively lowers serum phosphate levels to reduce cardiovascular risk
• Helps prevent or treat renal osteodystrophy by controlling phosphate accumulation
• Minimizes the risk of hypercalcemia through controlled calcium release
• Supports dietary flexibility by binding phosphate from various food sources
• Reduces the need for dietary phosphate restrictions
• May decrease the progression of vascular calcification in CKD patients

Common use

Phoslo is primarily prescribed for patients with end-stage renal disease who are on hemodialysis or peritoneal dialysis. It is used to control hyperphosphatemia (elevated phosphate levels in blood), a common complication of renal failure that can lead to serious health consequences including secondary hyperparathyroidism, bone disease, and soft tissue calcification. The medication is typically used as part of a comprehensive renal management program that includes dietary phosphate restriction and dialysis treatment.

Dosage and direction

The initial dosage for most adults is 2 tablets (1334 mg) with each meal. Dosage should be titrated gradually to bring serum phosphate level below 6.0 mg/dL, while avoiding hypercalcemia. The maximum recommended daily dose is 12 tablets (8004 mg). Tablets should be swallowed whole with water and taken at the beginning of each meal or immediately before eating. Dosage adjustments should be made under medical supervision based on regular monitoring of serum calcium and phosphate levels, typically every 2-3 weeks during initial therapy.

Precautions

Regular monitoring of serum calcium and phosphate levels is essential. Patients should maintain adequate hydration unless contraindicated. Those with conditions that predispose to hypercalcemia (such as sarcoidosis) require careful monitoring. Phoslo should be used cautiously in patients with digestive disorders that might affect absorption. Patients should inform their healthcare provider about all other medications they are taking. Calcium acetate may decrease the absorption of other medications when taken simultaneously.

Contraindications

Phoslo is contraindicated in patients with hypercalcemia (elevated serum calcium levels). It should not be used in patients with known hypersensitivity to calcium acetate or any component of the formulation. The medication is contraindicated in patients with low phosphate levels (hypophosphatemia). It is not recommended for patients with normal renal function or those not undergoing dialysis, as they do not require phosphate binding therapy.

Possible side effects

Common side effects may include nausea, vomiting, loss of appetite, constipation, and dry mouth. Hypercalcemia may occur, particularly with higher doses, manifesting as nausea, vomiting, anorexia, constipation, dry mouth, thirst, polyuria, and lethargy. Less frequently, patients may experience abdominal discomfort, diarrhea, or itching. Severe hypercalcemia may lead to confusion, delirium, stupor, and coma. Any persistent or severe side effects should be reported to a healthcare provider immediately.

Drug interaction

Phoslo may decrease the absorption of tetracycline antibiotics, quinolones, iron supplements, thyroid medications, and bisphosphonates when taken concurrently. These medications should be taken at least 1-2 hours before or 4-6 hours after Phoslo administration. Concurrent use with vitamin D supplements may increase the risk of hypercalcemia. Calcium-containing products may potentiate the effects of digitalis drugs. Patients should inform their physician about all prescription and over-the-counter medications they are taking.

Missed dose

If a dose is missed, it should be taken as soon as remembered with food. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should not double the dose to make up for a missed one. Consistent dosing with meals is important for optimal phosphate control. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy.

Overdose

Overdose may lead to hypercalcemia, which can cause nausea, vomiting, anorexia, constipation, dry mouth, thirst, polyuria, and lethargy. Severe hypercalcemia may progress to confusion, delirium, stupor, and coma. Treatment involves discontinuation of Phoslo, hydration, and monitoring of calcium levels. In severe cases, hospitalization may be required for intravenous fluids and other supportive measures. Hemodialysis against a low-calcium bath may be effective in reducing serum calcium levels in dialysis patients.

Storage

Store at room temperature between 15-30°C (59-86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use if the packaging is damaged or if tablets show signs of deterioration. Do not transfer to other containers unless specifically designed for medication storage. Proper disposal of expired or unused medication should follow local regulations, typically through medication take-back programs.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations. Individual response to medication may vary. The prescribing physician should be consulted for specific dosage instructions and monitoring requirements. Never initiate or discontinue medication without medical supervision.

Reviews

Clinical studies have demonstrated Phoslo’s effectiveness in controlling serum phosphate levels in dialysis patients. In comparative trials, calcium acetate has shown effective phosphate binding with potentially lower calcium absorption compared to other calcium-based binders. Many nephrologists report satisfactory phosphate control in their patients using Phoslo as part of comprehensive renal management. Patient experiences vary, with some reporting good tolerance while others may experience gastrointestinal side effects. Long-term use requires careful monitoring to balance phosphate control with calcium management.